Photo via AbbVie

AbbVie Receives CHMP Positive Opinion for Upadacitinib (RINVOQ™) for the Treatment of Adults with Moderate to Severe Active Rheumatoid Arthritis

Originally published on Abbvie.com

– CHMP positive opinion, supported by data from the pivotal Phase 3 SELECT rheumatoid arthritis program evaluating more than 4,400 patients, will now be referred to the European Commission for final approval[1-5]
– In Phase 3 trials, upadacitinib improved signs and symptoms of rheumatoid arthritis, inhibited radiographic progression and improved physical function, both as a monotherapy and in combination with conventional synthetic DMARDs[1-5]
– Upadacitinib (under the trade name RINVOQ™) is a selective and reversible JAK inhibitor discovered and developed by AbbVie[6]
NORTH CHICAGO, Ill., Oct. 18, 2019 /PRNewswire/ — AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for RINVOQ (upadacitinib), a once-daily selective and reversible JAK inhibitor, for the treatment of adult patients with moderate to severe active rheumatoid arthritis who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). The positive opinion is for use of upadacitinib as monotherapy or in combination with methotrexate.

The CHMP positive opinion is supported by data from the global Phase 3 SELECT rheumatoid arthritis program, evaluating more than 4,400 patients with moderate to severe active rheumatoid arthritis in five pivotal studies.1-5Across all five trials – SELECT-NEXT, SELECT-BEYOND, SELECT-MONOTHERAPY, SELECT-COMPARE and SELECT-EARLY – all primary and ranked secondary endpoints were met, including low disease activity based on Disease Activity Score 28 C-Reactive Protein (DAS28-CRP)≤3.2, clinical remission based on DAS28-CRP<2.6 and ACR20/50 (depending on study design); improved response was seen with upadacitinib both as monotherapy and in combination with conventional synthetic DMARDs compared to placebo, methotrexate or adalimumab (depending on study design).1-5 Data from the SELECT program showed a consistent safety profile across the five studies.1-5,7 The most frequently reported adverse reactions were infections.1-5

“Rheumatoid arthritis is a chronic and debilitating disease affecting an estimated 23.7 million people worldwide. While significant treatment advances have been made over the past 20 years, many people living with the disease still do not achieve remission. The need for novel, innovative treatment options is critical,” said Michael Severino, M.D., vice chairman and president, AbbVie. “We are pleased with this positive opinion from the CHMP recognizing upadacitinib’s potential for patients with moderate to severe active rheumatoid arthritis. This regulatory milestone marks an important step towards our pursuit of delivering innovative therapies that address the unmet needs of patients living with rheumatoid arthritis.”

The CHMP positive opinion is a scientific recommendation for marketing authorization to the European Commission, which authorizes marketing approval in the European Union. The Marketing Authorization will be valid in all member states of the European Union, as well as Iceland, Liechtenstein and Norway. The Commission decision is anticipated within 67 days following the CHMP opinion.

Leave a Comment

Your email address will not be published. Required fields are marked *

*

Latest News

Gainesville, Georgia, black, church,

Georgia Police Arrest White Teenager Before She Could Carry out Planned Attack on Black Churchgoers

A white female teenager has been arrested in Gainesville, Ga., after her high school peers told administrators on Friday about her notebook filled with plans to kill Black churchgoers at the Bethel African Methodist Episcopal Church, according to police. The 16-year-old girl was charged with criminal attempt to commit murder…

employees discrimination stylists white Black hair natural hair discrimination complaints Sharon Dorram Sally Hershberger New York City Commission On Human Rights

Swanky Salon First Business Penalized Under New York’s Hair Discrimination Legal Guidelines

A swanky salon on Manhattan’s Upper East Side has been penalized under the city’s hair discrimination law, New York City’s Human Rights Commission announced last week. Sharon Dorram Color at Sally Hershberger salon is the first business in New York City to face the consequences of discriminating against Black employees…

goodwill industries, settle, disability,

Goodwill Industries to Pay $65,000 to Settle Disability Discrimination Suit

Goodwill Industries of Greater New York and Northern New Jersey, Inc. touts its hiring of people with disabilities, but recently settled a workplace discrimination lawsuit for $65,000. The U.S. Equal Employment Opportunity Commission (EEOC) brought the lawsuit against Goodwill and announced Monday that the two groups had settled. According to…

ENGIE Chooses Accenture, Salesforce and Vlocity to Support its Customer Relations and Help Them Achieve Their Zero-Carbon Transition

Originally posted on Accenture.com With a global, unified industry-specific CRM, ENGIE is able to get a 360-degree customer view and help even more companies transition to zero-carbon energy SAN FRANCISCO, DREAMFORCE; Nov. 19, 2019 – Accenture (NYSE: ACN), Salesforce (NYSE: CRM) and Vlocity Inc. today announced the companies are teaming up with…

TIAA Holds SoPro Business Resource Group Summit

TIAA recently launched its 10th Business Resource Group (BRG): SoPro, for Seasoned Professionals of TIAA. The SoPro BRG’s mission is to maximize the impact of TIAA’s network of seasoned professionals by bridging generational differences and promoting cross-cultural collaboration by sharing knowledge and experiences. This includes future collaboration and partnership with…

Boeing Programs Receive Aviation Week Laureate Awards

Originally published on Boeing.mediaroom.com. ecoDemonstrator and Ground-based Midcourse Defense programs recognized for achievements in aerospace wo Boeing [NYSE:BA] programs were honored today with Aviation Week Laureate Awards for extraordinary achievements in aerospace. Boeing’s ecoDemonstrator program was recognized in the Commercial Aviation Sustainability category. The ecoDemonstrator takes promising technologies out of the…

Twitter

On Twitter, Activists, Businesses Can Advertise Causes, But Political Ads Still Banned

Twitter released revised rules for advertisements on Friday, saying that ads sponsored by politicians still are banned but advertisements for causes, such as social, economic and environmental issues, are allowed. Beginning this week, businesses and activists are allowed to buy advertisements around causes like “civic engagement” and “social equity.” But…